Special access program opens for investigational drug for inflammatory diseases
NCT ID NCT04159597
Summary
This program provides eligible patients with access to the drug upadacitinib for conditions like Crohn's disease, ulcerative colitis, and atopic dermatitis before it is officially approved in their country. A doctor must determine if the potential benefits for an individual patient outweigh the risks. The program is not for people who have other suitable treatment options or who qualify for ongoing clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.